Testing aminoglycoside antibiotics for early sepsis
Treatments studied
Part of Infections clinical trials.
This trial tests a type of antibiotic called aminoglycosides to treat early sepsis (a serious infection). It is for adults in the hospital who are sick enough to need strong antibiotics but not in the worst stage of the illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and currently staying in the hospital.
- Doctors think you have a serious infection (sepsis) that started in your community, and you need antibiotics right away.
- Your health score (NEWS2) is 5 or more, meaning you are moderately to severely ill.
- You do not have severe long-term kidney disease, septic shock, or certain other conditions like multiple myeloma or myasthenia gravis.
- You are not pregnant and have not had recent treatment with certain kidney-damaging drugs (like cisplatin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a computer tool to help doctors choose the right antibiotic for sepsis early on. It may help improve treatment by providing personalized recommendations based on your condition.
This study tests how well aminoglycoside antibiotics work in people with sepsis who also have low kidney function. It may help find the best way to treat serious infections in patients with kidney problems.
This trial compares two common antibiotics, meropenem and piperacillin/tazobactam, to see which works better for adults with sepsis who are critically ill. It aims to help doctors choose the best treatment for serious infections.
This trial tests whether giving a certain type of antibiotic (beta-lactam) continuously or intermittently works better for patients in the intensive care unit with pneumonia or a urinary tract infection and signs of sepsis. Sepsis is a serious response to an infection, so better antibiotic delivery could improve outcomes.
This trial compares giving a long, continuous infusion versus standard short infusions of certain antibiotics (beta-lactams) to children with sepsis in intensive care. The goal is to find which method works better and is safer.
This trial is looking for patients who have an infection and are showing early signs of getting sicker, like a high warning score. It aims to find out if doctors can identify those at risk of sepsis sooner so they can start treatment earlier.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.